Skip to main content

US ClosedU.S. Closed

Healthcare · Biotechnology

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies.

52W Range

11thpctl

Volume

0.38×avg

Market Cap

160.67MUSD

P/E Ratio

-1.5TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Caribou Biosciences, Inc.

CRBUNASDAQ Global Select·USD·Closed

Caribou Biosciences, Inc.

CRBUNASDAQ·USD·Closed

$1.62

−2.41%

$1.62

−$0.04 (2.41%)

52W Range

11thpctl

Volume

0.38×avg

Mkt Cap

160.67MUSD

P/E

-1.5TTM

Div Yield

–ann

CRBU: Caribou Biosciences, Inc. Stock Analysis | finqOS